TOP TIERMARKET NEWSWIRE
News & sentiment

OVID THERAPEUTICS IN (OVID) — News & AI sentiment

OVID THERAPEUTICS IN (OVID) news roundup. 7 stories aggregated over the last 30 days. Average 30-day sentiment is 60/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
7
avg sentiment 60/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

Latest stories on OVID

B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target
Investing.com Analyst Ratings61 · neutralanalyst
Jul 21
Jul 14
Jul 8
Ovid Therapeutics Inc. (OVID) files 8-K
SEC 8-K50 · neutralgeneral
Jul 8
Jul 8
Jul 8
Jul 7
Ovid Therapeutics Inc. (OVID) files 8-K
SEC 8-K50 · neutralgeneral
Jun 11
Jun 4
Jun 3
Jun 3
Open OVID in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →